TP53 and B-cell chronic lymphocytic leukemia: It was equally effective against these primary CLL cells (n = 28) as against those derived from clinically relapsed CLL patients (n = 10), including those harboring p53 deletion (n = 3) while exhibiting superior bioavailability than Flavopiridol.